神奇制药：因2023年报差错遭上海证监局责令改正

Core Viewpoint - The company, Shenqi Pharmaceutical, has disclosed a rectification report and an announcement regarding accounting errors, following a decision from the Shanghai Securities Regulatory Bureau due to discrepancies in its 2023 annual report [1] Financial Adjustments - The company has adopted a retrospective restatement method to adjust its 2023 financial data, reducing sales expenses from 909.41 million yuan by 44.84 million yuan to 864.57 million yuan, and credit impairment losses from 47.69 million yuan by 44.84 million yuan to 2.85 million yuan [1] - In the consolidated cash flow statement, cash received from sales was adjusted down from 2,124.00 million yuan by 44.84 million yuan to 2,079.16 million yuan, while cash received from other operating activities was increased by 44.84 million yuan to 266.39 million yuan [1] Recent Financial Performance - For the third quarter of 2025, the company reported revenue of 437 million yuan, a year-on-year decline of 3.51%, and a net profit attributable to shareholders of 17.49 million yuan, down 18.7% year-on-year [1] - The company's net profit excluding non-recurring items was 16.03 million yuan, reflecting a year-on-year decrease of 19.74%, with net cash flow from operating activities amounting to 110 million yuan [1]